CAM
SRNE

Cormorant Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Cormorant Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-400,000
Closed -$3.05M – 95
2021
Q3 		$3.05M Sell
400,000
-100,000
-20% -$848K 0.12% 79
2021
Q2 		$4.84M Sell
500,000
-2,250,000
-82% -$17.9M 0.16% 82
2021
Q1 		$22.7M Sell
2,750,000
-1,750,000
-39% -$18.5M 0.51% 44
2020
Q4 		$30.7M Sell
4,500,000
-1,500,000
-25% -$12M 0.73% 36
2020
Q3 		$66.9M Sell
6,000,000
-500,000
-8% -$4.58M 2.57% 9
2020
Q2 		$40.8M Buy
6,500,000
+1,500,000
+30% +$5.74M 1.56% 24
2020
Q1 		$9.2M Buy
5,000,000
+1,000,000
+25% +$2.88M 0.43% 50
2019
Q4 		$13.5M Buy
+4,000,000
New +$9.54M 0.54% 47
2017
Q3 		– Sell
-1,690,800
Closed -$3.38M – 69
2017
Q2 		$3.38M Hold
1,690,800
– – 0.56% 46
2017
Q1 		$6.68M Sell
1,690,800
-218,200
-11% -$1.09M 0.97% 33
2016
Q4 		$9.35M Sell
1,909,000
-212,013
-10% -$1.27M 1.26% 26
2016
Q3 		$16.4M Hold
2,121,013
– – 1.81% 20
2016
Q2 		$11.9M Buy
2,121,013
+25,679
+1% +$164K 1.68% 22
2016
Q1 		$11.3M Hold
2,095,334
– – 1.7% 23
2015
Q4 		$18.3M Hold
2,095,334
– – 2.18% 13
2015
Q3 		$17.6M Buy
2,095,334
+150,000
+8% +$2.39M 2.81% 10
2015
Q2 		$34.3M Buy
1,945,334
+292,422
+18% +$3.76M 4.56% 7
2015
Q1 		$19.1M Sell
1,652,912
-97,088
-6% -$1.12M 2.95% 8
2014
Q4 		$17.6M Buy
1,750,000
+750,000
+75% +$3.8M 2.72% 11
2014
Q3 		$4.52M Hold
1,000,000
– – 0.93% 32
2014
Q2 		$6.75M Buy
1,000,000
+300,000
+43% +$2.26M 1.79% 21
2014
Q1 		$8.97M Buy
+700,000
New +$7.75M 2.06% 18

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cormorant Asset Management's SRNE Position: Q4 2021 in Review

Cormorant Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2021, closing a stake of 400,000 shares — an estimated $3.05M sold.

Cormorant Asset Management first reported a position in SRNE in Q1 2014 and held it in 22 quarters. The position peaked at $66.9M in Q3 2020. 234 funds tracked by Wall St. Rank hold SRNE as of Q4 2021.

  • Cormorant Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 400,000 Sorrento Therapeutics, Inc. shares in Q4 2021, an estimated $3.05M.
  • Cormorant Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2014 and held it in 22 quarters.
  • Cormorant Asset Management's Sorrento Therapeutics, Inc. position peaked at $66.9M in Q3 2020.
  • 234 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2021.

Based on Cormorant Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.